At its peak, the Risperdal litigation had more than 7,000 cases pending in Philadelphia, making it one of the largest mass torts to come through the city’s busy complex litigation center. And with a city jury returning a historic $8 billion award, it was also one of the most successful for plaintiffs.

The inventory has been steadily declining over the past two years after, according to records obtained by, including a settlement offer, the main defendants and law firms representing the majority of clients entered into a settlement for up to $1.1 billion.